← FDA DRUG APPROVALS

FDA ANDA · ANDA203322

SUMATRIPTAN SUCCINATE

Sponsor: NORVIUM BIOSCIENCE

APPLICATION
ANDA203322
TYPE
ANDA
ORIGINAL APPROVAL
2014-04-14
LATEST ACTION
2014-04-14
ROUTE
SUBCUTANEOUS
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Discontinued

Products

SUMATRIPTAN SUCCINATEDiscontinued
SUMATRIPTAN SUCCINATE EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) · INJECTABLE · SUBCUTANEOUS

Approval history

2014-04-14UNKNOWN · OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →